Prognostic Molecular and Environmental Factors in High-Risk Colon Cancer Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00354705|
Recruitment Status : Active, not recruiting
First Posted : July 20, 2006
Last Update Posted : October 4, 2018
|Condition or disease||Intervention/treatment|
|Colon Cancer||Behavioral: Questionnaire|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||Prognostic Molecular and Environmental Factors in High-Risk Stage II and Stage III Colon Cancer Patients|
|Actual Study Start Date :||January 2006|
|Estimated Primary Completion Date :||January 2020|
|Estimated Study Completion Date :||January 2020|
Colon Cancer Patients
Patients with colon cancer recently removed by surgery.
Two questionnaires taking 30 minutes to complete.
Other Name: Survey
- Occurence of Recurrent Colon Cancer [ Time Frame: Information collected at 1, 2 and 3 years after completion of adjuvant chemotherapy or at the time of reoccurrence. ]Study endpoint is occurrence of recurrent colon carcinoma determined radiologically and/or histologically.
Biospecimen Retention: Samples With DNA
20 ml of blood for genomic analysis collected at baseline, at completion of adjuvant chemotherapy ( <28 days after its completion) if applicable, at each subsequent surveillance visit (every 3 months after discontinuation of adjuvant chemotherapy, continuing for 2 years), and at time of disease recurrence, if applicable.
20 ml of blood for proteomic analysis studies collected at baseline, at completion of adjuvant chemotherapy, if applicable ( <28 days after its completion), and at time of disease recurrence, if applicable.
Tissue (0.2gm of tissue) from primary resection obtained at time of study enrollment. A tissue sample (0.2gm of tissue) also obtained, if possible, from patients that require surgical intervention at M.D. Anderson Cancer Center, for recurrent disease.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00354705
|United States, Texas|
|University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Cathy Eng, MD||M.D. Anderson Cancer Center|